Aurobindo Pharma Limited has reported a consolidated net profit of Rs. 824 crore in the quarter ended June 2025 (Q1 FY26) against Rs. 918 crore in Q1 FY25, reflecting a drop of 10.20% on a year-on-year basis.

For Q1 FY26, Aurobindo clocked revenue from operations of Rs. 7,868 crore as compared to Rs. 7,567 crore in the same quarter of previous year, reflecting a 4% YoY growth.

The company announced an operating EBITDA of Rs. 1,603 crore in Q1 FY26 as compared to Rs. 1,619.60 crore in Q1 FY25.  The EBITDA margin slipped to 20.4% on a year-on-year basis against 21.4% in the previous corresponding period.

Aurobindo Pharma’s US formulations revenue slipped 1.9% on a year-on-year basis to Rs. 3,488 crore (US$ 408 million). This was impacted by destocking and seasonal headwinds. However, its European formulations business remains robust. It registered an 18% year-on-year growth to Rs. 2,338 crore (EUR 241 million).

Revenue from growth markets witnessed 8.80% growth to Rs.772 crore. While revenue from the Active Pharmaceutical Ingredients (API) segment slipped as much as 16% year-on-year to Rs. 916 crore.

Commenting on the company’s performance, K. Nithyananda Reddy, Vice-Chairman and Managing Director of the company said: “We started the year steadily, with our European business maintaining strong growth momentum and our core US business showing resilience despite temporary challenges from destocking and seasonal dynamics. Our disciplined execution, operational initiatives, and recent US acquisition strengthens our commercial footprint and accelerates growth potential.”